Enter multiple symbols separated by commas

Stocks Teva Pharmaceutical Industries Ltd


  • Cramer makes the call on viewers' favorite stocks.

  • Dow In Striking Distance Of 11,000 Tuesday, 23 Mar 2010 | 5:37 PM ET

    The Dow is now up 10 out of 11 days and within striking distance of 11,000. Will the melt-up propel us over this milestone?

  • The Human Tragedy Behind A Drug Deal Monday, 22 Mar 2010 | 2:03 PM ET

    Shares of Teva Pharmaceutical Industries are once again trading at an historic high. But they might not be there today if it weren’t for a tragedy.

  • 8 Top Dividend Plays from 2 Top Strategists Monday, 22 Mar 2010 | 11:50 AM ET

    Many companies are announcing dividend hikes this month—a reversal from last year and the year before. So where should investors place their money? Jeff Krumpelman, dividend growth portfolio manager at Hilliard Lyons Capital Management, and Stanley Nabi, chief strategist at Silvercrest Asset Management, offered their best dividend plays.

  • Pfizer’s Kindler KO’d by Teva’s Yanai Thursday, 18 Mar 2010 | 3:41 PM ET
    Teva and Pfizer

    The 800-pound gorilla of one industry has beaten the 800-pound gorilla of another. Teva CEO Shlomo Yanai took on Pfizer CEO Jeff Kindler and won.

  • Hot Trades: Regional Banks, Retail & More... Thursday, 11 Mar 2010 | 5:44 PM ET

    If you're looking for a trading idea, you might want to check out regional banks or the retailers. Find out why!

  • February goes down in the books as an up month that has put the market back to flat for 2010. How should you be positioned for March?

  • Playing Stock Market With Contrarian Bets Monday, 22 Feb 2010 | 6:06 PM ET

    Over the next few weeks, I feel confident that’s how investors will make money, says veteran trader Gary Kaminksy – with contrarian trades.

  • Bet on Generics? Monday, 22 Feb 2010 | 5:46 PM ET

    With Barron’s turning very bullish on generic drugmaker Mylan Labs, should you put money to work in the generic space?

  • Earnings Roundup: Feb. 16 Friday, 12 Feb 2010 | 5:06 PM ET

    What follows is a roundup of corporate earnings reports for Tuesday, Feb. 15.

  • In an Uncertain Market, Quality is King Wednesday, 10 Feb 2010 | 6:20 PM ET

    On a day when the market seemed confused - moving within relatively a wide range and ending the day to the downside - there were many reasons why this confusion was warranted.

  • On a day where markets are rattled by sovereign debt issues, yet encouraged that a European bailout of Greece may be imminent, markets have also reacted to domestic developments.

  • Generic Drugs and The 'Maris' Poll Friday, 29 Jan 2010 | 9:47 AM ET

    Three out of four prescriptions in the U.S. are filled with generics. But a new, albeit small, survey by a prominent generic drug industry analyst shows even the people filling those pill bottles have issues with generics.

  • Markets rose on Monday, rebounding off of their worst week since last March. What should investors expect going forward? Dan Genter of RNC Capital Management and David Hefty of Cornerstone Wealth Management shared their outlooks, sector and stock picks.

  • Your First Move For Monday January 25th Friday, 22 Jan 2010 | 6:15 PM ET

    Here’s our Fast Money Final Trade. Our gang gives you Monday’s best trades, right now.

  • haiti_earthquake_10_200.jpg

    Corporate donations to the relief effort in Haiti now total more than $106 million according to the U.S. Chamber of Commerce, surpassing the $100 million in aid initially pledged by the U.S. government. 

  • Lightning Round: Verizon, 3Com, Corning and More Monday, 11 Jan 2010 | 10:15 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Health Care Watch List Friday, 8 Jan 2010 | 5:31 PM ET

    The traders are closely watching potential hot stocks ahead of the JPMorgan Health Care conference next week.

  • Topping The Tape: HMOs Tuesday, 22 Dec 2009 | 5:54 PM ET

    HMO stocks traded higher as some Dems predicted health care reform could pass as soon as Christmas Eve.

  • Pharma’s Holiday Shopping Spree Monday, 21 Dec 2009 | 1:13 PM ET

    This morning biopharma P & A reached critical mass. In a rare, holiday-week confluence, four major pharmaceutical companies announced partnership deals and one announced a nearly $2-billion acquisition. All of the partnerships are on drugs that are still in the testing stage. If they were to all come to fruition, which in the risky business of drug development is highly unlikely, the new partnerships could collectively be worth billions of dollars over time.